Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,813 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07164183RecruitingPhase 3
Comparing two drugs for endometriosis pain relief
This study tests if a new drug called Indinol Forto works as well as the standard drug Visanne for reducing endometriosis-related pelvic pain. It is for women with surgically confirmed endometriosis who have regular cycles and moderate to severe pain.
Kazan'Ages 18–45 - NCT07164170RecruitingPhase 2
Study of ABSK043 plus Glecirasib for advanced NSCLC
This trial tests a combination of two experimental drugs, ABSK043 and Glecirasib, for people with a specific type of advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination works better than standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07165223RecruitingPhase 3
Testing a new insulin for type 2 diabetes
This trial tests a new weekly insulin called GZR4 for people with type 2 diabetes who already use basal insulin. It aims to see how well it controls blood sugar and if it is safe.
Linyi, ShandongAges 18 years+ - NCT07166757RecruitingPhase 1/Phase 2
Study of XS411 for early-onset Parkinson's disease
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07170800RecruitingPhase 2
Study of JDB0131 for drug-resistant TB
This trial tests a new tablet called JDB0131 for people with tuberculosis (TB) that is resistant to the antibiotic rifampicin. The goal is to see if it can effectively treat this hard-to-treat form of TB.
Wuhan, HubeiAges 14 years+ - NCT07175220RecruitingPhase 2
Study of SHR2554 tablets combined with other treatments for lung cancer
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
Guangzhou, GuangdongAges 18–75 - NCT07176208RecruitingPhase 1
THC and alcohol effects on driving in healthy adults
This study looks at how taking THC (the active ingredient in cannabis) with or without alcohol affects your driving and perception. You will take a THC pill and possibly a drink with alcohol, then have your driving tested in a simulator.
West Bend, WisconsinAges 21–55 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07179679RecruitingPhase 1
Study of a new shot for multiple myeloma
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07185035RecruitingEarly Phase 1
Testing natural killer cells for leftover lung nodules
This trial is testing a new treatment using your own immune cells (called NK cells) to fight leftover high-risk lung nodules that cannot be surgically removed. It is for people who have already had some cancerous nodules removed and are looking for another option.
NanjingAges 18–70 - NCT07187518Recruiting
Testing a new ultrasound device for bone density
This study tests a new ultrasound device (POROUS R4C) to see if it can accurately estimate bone mineral density. If it works well, it could offer a quick, radiation-free way to check bone health.
BerlinAges 21–55 - NCT07193589RecruitingPhase 2
Testing ZL-82 tablets for moderate to severe eczema
This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.
Chengdu, SichuanAges 18–75 - NCT07198555RecruitingPhase 1
Study of BBM-A101 for knee osteoarthritis
This trial tests a new medicine called BBM-A101 for people with moderate knee osteoarthritis. It aims to see if it is safe and helps reduce pain and improve function.
Shenzhen, GuangdongAges 40–75 - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT07205536RecruitingPhase 2
Preventing low white blood cells during chemo-radiation for chest cancers
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Nantong, JiangsuAges 18–75 - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07215650RecruitingPhase 1
Cizutamig for generalized myasthenia gravis
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07215663RecruitingPhase 1
Cizutamig for active lupus not helped by other treatments
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
BeijingAges 18–75 - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07216885Recruiting
Testing a new hemodialysis machine in a dialysis center
This study tests a new dialysis machine called the Solv Multi-Pass System in a dialysis center. It looks at whether the machine works safely and effectively for people with end-stage kidney disease who need regular hemodialysis.
Greenville, South CarolinaAges 18 years+ - NCT07229768RecruitingEarly Phase 1
Study of 177Lu-CTR-FAPI for advanced solid tumors
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
ShanghaiAges 18–85 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,813 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.